Travis Alvin Thompson net worth and biography

Travis Thompson Biography and Net Worth

Travis Thompson is the CAO of Bicycle Therapeutics.

What is Travis Alvin Thompson's net worth?: The estimated net worth of Travis Alvin Thompson is at least $222.75 thousand as of October 3rd, 2025. Thompson owns 31,197 shares of Bicycle Therapeutics stock worth more than $222,747 as of December 5th. This net worth estimate does not reflect any other assets that Thompson may own. Learn More about Travis Alvin Thompson's net worth.
How do I contact Travis Alvin Thompson?: The corporate mailing address for Thompson and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Travis Alvin Thompson's contact information.
Has Travis Alvin Thompson been buying or selling shares of Bicycle Therapeutics?: Over the course of the past ninety days, Travis Alvin Thompson has sold $2,722.63 of Bicycle Therapeutics stock. Most recently, Travis Alvin Thompson sold 103 shares of the business's stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $8.41, for a transaction totalling $866.23. Following the completion of the sale, the chief accounting officer now directly owns 31,197 shares of the company's stock, valued at $262,366.77. Learn More on Travis Alvin Thompson's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Santiago Arroyo (Insider), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), Pierre Legault (Director), Alistair Milnes (COO), Michael Skynner (CTO), Travis Thompson (CAO), and Alethia Young (CFO). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, Bicycle Therapeutics insiders bought shares 2 times. They purchased a total of 1,485,397 shares worth more than $21,229,062.72. In the last twelve months, insiders at the sold shares 28 times. They sold a total of 49,366 shares worth more than $563,681.34. The most recent insider tranaction occured on October, 3rd when CEO Kevin Lee sold 3,231 shares worth more than $27,172.71. Insiders at Bicycle Therapeutics own 22.9% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 10/3/2025.

Travis Alvin Thompson Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/3/2025	Sell	103	$8.41	$866.23	31,197
10/2/2025	Sell	221	$8.40	$1,856.40	31,300
7/3/2025	Sell	100	$7.44	$744.00	31,521
7/2/2025	Sell	206	$7.09	$1,460.54	31,621
4/2/2025	Sell	210	$8.02	$1,684.20	31,936
1/6/2025	Sell	2,686	$15.00	$40,290.00	32,146
1/2/2025	Sell	1,750	$14.09	$24,657.50	34,991
11/11/2024	Sell	6,256	$25.11	$157,088.16	19,241
10/3/2024	Sell	153	$22.26	$3,405.78	22,922
7/3/2024	Sell	148	$19.64	$2,906.72	23,075
4/3/2024	Sell	152	$23.81	$3,619.12	23,223
1/3/2024	Sell	604	$17.50	$10,570.00	23,375
10/3/2023	Sell	54	$20.00	$1,080.00	7,979
7/3/2023	Sell	61	$25.10	$1,531.10	8,033

Travis Alvin Thompson Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $7.14

$6.96

$7.27

50 Day Range

MA: $7.48

$6.17

$8.87

2 Week Range

Now: $7.14

$6.03

$21.50

Volume

302,559 shs

Average Volume

327,116 shs

Market Capitalization

$495.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47